Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial

Journal of Clinical Oncology

Volumn 20, Issue 3, 2002, Pages 630-637

  Horning, Sandra J ^a   Hoppe, Richard T ^a   Breslin, Sheila ^a   Bartlett, Nancy L ^a   William Brown, B ^a   Rosenberg, Saul A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HODGKIN DISEASE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PREGNANCY; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036467658     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.3.630     Document Type: Article

References (31)

1. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP
2. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: The Milan experience
3. Treatment of advanced Hodgkin's disease with chemotherapy: Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD. A report from the national cancer institute of Canada clinical trials group
4. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
5. MOPP/ABV versus ABVD for advanced Hodgkin's disease: A preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC)
6. Gonadal toxicity after combination chemotherapy for Hodgkin's disease: Comparative results of MOPP vs ABVD
7. Treatment of advancedstage massive mediastinal Hodgkin's disease: The case for combined modality treatment
8. Hodgkin's disease with bulky mediastinal involvement: Effective management with combined modality therapy
9. Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study
10. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy
11. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease: A Southwest oncology group randomized study
12. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease: German Hodgkins' study group (GHSG)
13. Long term complications of treatment and causes of mortality after Hodgkin's disease
14. Breast cancer after treatment of Hodgkin's disease
15. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease: International database on Hodgkin's disease overview study group
16. Brief chemotherapy and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report
17. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update
18. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern cooperative oncology group pilot study E 1492
19. A prognostic score for advanced Hodgkin's disease: International prognostic factors project on advanced Hodgkin's disease
20. Report of the committee on the Hodgkin's disease staging
21. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: The Stanford experience
22. Non-parametric estimation of incomplete observations
23. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
24. Asymptotically efficient rank invariant test procedures
25. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices
26. Primary refractory Hodgkin's disease
27. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure?
28. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease: German Hodgkin's Lymphoma study group
29. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease-The German Hodgkin's lymphoma study group
30. BEACOPPa new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's lymphoma study group
31. Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: Updated results of the German Hodgkin's lymphoma study group